FULC - Company ID 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $0.00 | - | $0.00 | $80.00M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $14.08M | $14.30M | $12.99M | $13.40M | $14.64M | $17.26M |
Fulcrum Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $80.00M in fiscal 2024. Over the 6 fiscal years shown, annual revenue declined from $8.82M (FY 2020) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $8.10M |
| $7.56M |
| $6.83M |
| $7.00M |
| $8.42M |
| $10.25M |
| Operating income | -$22.19M | -$21.86M | -$19.82M | -$20.40M | -$25.13M | $52.49M |
| Income tax | - | - | - | - | - | - |
| Net income | -$18.89M | -$19.59M | -$17.30M | -$17.66M | -$21.70M | $55.41M |
| EPS (diluted) | -$0.25 | -$0.31 | -$0.28 | -$0.28 | -$0.35 | $0.87 |